Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Doctors removed her cancerous tongue and, using a flap of skin from her forearm, created a new tongue. Her grafted skin had ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a press release.With this approval, Zevaskyn (prademagene zamikeracel, Abeona) ...

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday. The ...

The Gibraltar Health Authority will hold its annual Skin Cancer Screening Day on May 10 at the Primary Care Centre, offering members of the public the opportunity to have skin lesions or changing ...

Over 25,000 people in the UK are diagnosed with squamous cell carcinoma every year. Yet thousands do not know the vital signs ...

Artificial intelligence models, pretrained on vast datasets, significantly outperformed a standard baseline model in ...

As the weather warms up, more people will be out in the sun, and the Skin Cancer Foundation wants to make sure everyone stays ...

To amputate or save a limb? Philly’s tranq crisis is forcing doctors to make difficult choices amid a slow public health ...

Researchers used tissue samples from patients with an inflammatory skin disease called hidradenitis suppurativa to gain insights into inflammation patterns before and after drug exposure.

IDO1 and PDL1 are immune checkpoints with key roles in immune system regulation. Their relevance stems from their ability to suppress T-cell function. T-cells are vital to the body’s immune response ...